Pharmaceutical - Pharmaceutical

Filter

Current filters:

Pharmaceutical

Popular Filters

6801 to 6825 of 7049 results

Letter to the Editor: Canadian intellectual property

10-11-2011

Dear, The Pharma Letter: The characterization of the CMAJ article by Paul Grootendorst and Aidan Hollis…

GenericsNorth AmericaPatentsPharmaceutical

Kohl-Grassley generic drug bill would save US taxpayers nearly $4.8 billion, says CBO

09-11-2011

A new estimate from the USA’s Congressional Budget Office (CBO) estimate finds that a bipartisan…

GenericsNorth AmericaPatentsPharmaceuticalPoliticsPricing

Salix Pharma to buy Oceana for $300 million; posts 3rd-qtr profit

09-11-2011

With the aim of improving its innovate products franchise, US drugmaker Salix Pharmaceuticals (Nasdaq:…

FinancialMergers & AcquisitionsOceana TherapeuticsPharmaceuticalSalix Pharmaceuticals

Merck Serono expands osteoarthritis collaboration with Ablynx

09-11-2011

Merck Serono, a division of Germany’s Merck KGaA (MRK: DE) has entered into a third agreement with…

AblynxAnti-Arthritics/RheumaticsLicensingMerck SeronoPharmaceuticalResearch

Timothy Wright named global head, development, at Novartis Pharma

09-11-2011

Swiss drug major Novartis (NOVN: VX) announced the appointment of Timothy Wright, as global head, development,…

ManagementNovartisPharmaceutical

Amylin diabetes drug exenatide deal with Eli Lilly terminated, with $1.45 billion settlement to Lilly

09-11-2011

Shares of US biotech firm Amylin Pharmaceuticals fell 8.4% to $10.01 in pre-market trading yesterday,…

AmylinBiotechnologyBydureonByettaDiabetesEli LillyExenatide InjectionLicensingPharmaceutical

Disappointment for AstraZeneca and Targacept as antidepressant fails to meet Ph III endpoint

09-11-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and Targacept (Nasdaq: TRGT) yesterday reported disappointing…

AstraZenecaNeurologicalPharmaceuticalResearchTargacept

Transgene to seek partner for HCV vaccine TG4040 on strong Ph II results

09-11-2011

French biotech firm Transgene (Euronext Paris: FR0005175080) has revealed interim data showing a substantial…

BiotechnologyLicensingOncologyPharmaceuticalResearchTransgeneVaccines

Strong 3rd-quarter 2011 sales growth at Lundbeck, but write-off hits profit

09-11-2011

Danish CNS drug specialist Lundbeck (LUND: DC) has reported a strong set of financial results for the…

FinancialLundbeckNeurologicalPharmaceutical

Tranzyme Pharma extends drug discovery collaboration with Bristol-Myers Squibb

09-11-2011

USA-based Tranzyme Pharma (Nasdaq: TZYM) says it has extended its chemistry-based drug discovery collaboration…

Bristol-Myers SquibbLicensingPharmaceuticalResearchTranzyme

Will the USA’s Hatch-Waxman lock be sprung in 2012? asks HP&M lawyer

08-11-2011

In the USA, there have been rumors for several weeks that, once the ball gets rolling in Congress with…

GenericsLegalNorth AmericaPharmaceuticalPoliticsRegulation

Recordati’s Normosang now approved in Russia; posts strong financials

08-11-2011

Italian drugmaker Recordati (REC: MI) and wholly-owned subsidiary Orphan Europe announced that Normosang,…

EuropeFinancialNormosangPharmaceuticalRare diseasesRecordatiRegulation

Another call for reform of Canada’s pharma intellectual property laws

08-11-2011

Canada's pharmaceutical intellectual property laws need major reform to encourage and protect innovation…

North AmericaPatentsPharmaceutical

Emerging therapies will drive prostate cancer drug market to $10.1 billion in 2020

08-11-2011

Driven by the launches of several promising emerging therapies, the prostate cancer drug market will…

Astellas PharmaBiotechnologyGlobalJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalZytiga

South Korean govt to slash drug prices 14%

08-11-2011

South Korea’s Ministry of Health and Welfare has issued an advance notice of the legislation of…

Asia-PacificPharmaceuticalPoliticsPricingResearch

FDA accepts VIVUS NDA filing for Qnexa with PDUFA set for April 2012

08-11-2011

There was good news for US drugmaker VIVUS (Nasdaq: VVUS) in its long-running battle to get its weight-loss…

MetabolicsNorth AmericaPharmaceuticalQnexaRegulationVivus

Added indication for Bristol-Myers’ Erbitux approved by FDA

08-11-2011

The US Food and Drug Administration yesterday approved US drug major Bristol-Meyers Squibb’s (NYSE:…

Bristol-Myers SquibbErbituxNorth AmericaOncologyPharmaceuticalRegulation

Vertex’ Incivek set to break record for fastest product launch

08-11-2011

Vertex Pharmaceuticals’ (Nasdaq: VRTX) new hepatitis C drug Incivek (telaprevir) is being touted…

FinancialIncivekMarkets & MarketingPharmaceuticalVertex

AstraZeneca launches new Crestor savings card in USA, as generic Lipitor about to debut

07-11-2011

The US subsidiary of Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday launched a new savings…

AstraZenecaCardio-vascularCrestorGenericsLipitorNorth AmericaPfizerPharmaceuticalPricing

Novo Nordisk says DegludecPlus provides superior glycemic control vs Lantus

07-11-2011

Denmark-based insulin giant Novo Nordisk (NVO: N) yesterday announced positive clinical results from…

DegludecDegludecPlusDiabetesLantusNovo NordiskPharmaceuticalResearchSanofi

Small-molecule cancer drug revenues set to reach $27.3 billion in 2015, predicts Visiongain

07-11-2011

Rising disease prevalence, along with advances in pharmacotherapy and diagnostics, will stimulate the…

Markets & MarketingOncologyPharmaceutical

Study identifies factors linked with better medication response for treatment of juvenile arthritis

07-11-2011

Among patients with juvenile idiopathic arthritis (JIA) who initiated treatment with the drug etanercept…

AmgenAnti-Arthritics/RheumaticsEnbreletanerceptPfizerPharmaceuticalResearch

US FDA clears Bayer/Johnson & Johnson’s Xarelto for stroke risk reduction in AF patients

07-11-2011

In what was much-awaited good news for German drug major Bayer (BAY: DE), its US subsidiary announced…

BayerCardio-vascularJanssen PharmaceuticaJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Pfizer returns rights to TNF-alpha targeting nanobodies to Ablynx

07-11-2011

Shares of Belgian drug developer Ablynx [Euronext Brussels: ABLX] fell 18.2% to 2.93 euros in morning…

AblynxAnti-Arthritics/RheumaticsLicensingozoralizumabPfizerPharmaceutical

6801 to 6825 of 7049 results

Back to top